drugset / Trial / NCT00580190
Evaluation Of PF-00572778 And Alprazolam On Naloxone Challenge In Healthy Subjects
RandomizedParallel-groupSingle-blindTreatment
Summary
PF-00572778, a CRH antagonist, is expected to attenuate adrenocorticotropin (ACTH) and cortisol responses to naloxone by blocking the effect of the CRH increases induced by naloxone at the postsynaptic receptors. Demonstration of a statistically significant attenuation of naloxone induced increases in cortisol and/or ACTH concentrations by PF-00572778 compared to placebo would thus constitute proof of mechanism for the compound. Therefore, this study is to evaluate pharmacodynamic effects of PF-00572778 following naloxone challenge in healthy subjects.
Timeline
- Start
- 2007-09
- Primary completion
- —
- Completion
- 2008-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Alprazolam | Small molecule | 0.5 mg | — |
| Subject | PF-00572778 | Unknown | 500 mg | — |
Indications
No indication recorded.